Kardiologie up2date 2009; 5(2): 90-95
DOI: 10.1055/s-0029-1214639
Hotline – Herzrhythmusstörungen

© Georg Thieme Verlag KG Stuttgart · New York

Neue Medikamente zur Behandlung von Vorhofflimmern – gibt es eine Alternative zu Amiodaron?

Alexander  Bauer, Hugo  A.  Katus
Further Information

Publication History

Publication Date:
01 July 2009 (online)


Atrial fibrillation is the most common arrhythmia requiring treatment interventions with a high prevalence in elderly patients. In elderly asymptomatic patients rate control is the therapy of choice, whereas in symptomatic patients antiarrhythmic therapy or pulmonary vein isolation would be preferred. However, many currently used antiarrhythmic drugs have limited efficacy and cause irreversible organ toxicity. Amiodarone is the most potent antiarrhythmic agent for the treatment of atrial fibrillation. However, its use is limited by toxic effects on thyroid, lungs, liver, cornea, skin, and peripheral nerves. Thus compound development is more focused on congeners of Amiodarone. Dronedarone is a noniodinated benzofuran with similar electrophysiological effects compared to Amiodarone. Other compounds are under investigation. This review summarizes preclinical and clinical findings of these agents.


Prof. Dr. med Alexander Bauer

Abteilung Kardiologie, Angiologie und Pneumologie
Universitätsklinikum Heidelberg

Im Neuenheimer Feld 410
69120 Heidelberg

Email: Alexander.Bauer@med.uni-heidelberg.de